360° SearchNetwork Hot Spots Trends Time Series

Tradjenta

Type: Product

Name: Tradjenta

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Tradjenta Coupon - The Things You Nee...

The down slope of nowadays' economy has made it much more impossible for folks to live a bountiful, joyous and healthful life. Everything appeared to be constraint specifically to those who have small income. The fact is, it is almost impossible to pay ... [Published Al Bawaba - May 18 2013]

Entities: Tradjenta, Cheap, Imprinting, Drugs

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Boehringer Ingelheim GmbH

Retrospective Analysis Of Linagliptin Data In Sub-populations With Type 2 Diabetes Presented At AACE 22nd Annual Scientific & Clinical Congress

RIDGEFIELD, Conn.In one retrospective pooled analysis, data were included from Hispanic/Latino adults with type 2 diabetes (T2D), a population that is disproportionately affected by T2D. 1 Data pooled from six phase III studies showed that treatment with ... [Published TheStreet.com - May 06 2013]

Entities: Linagliptin, Tradjenta, Diabetes Type II, Boehringer Ingelheim GmbH, Placebo

First reported Apr 24 2013 - Updated Apr 25 2013 - 1 reports

Higher prices keep Lilly's quarter flat; Cymbalta DTC pull-back planned

Eli Lilly wrapped the first quarter with flat results, and a lot of open threads. The company said Wednesday that sales for the three months were $5.6 billion, just as they were for the same period last year.Lilly faces a slew of changes, including firing ... [Published Medical Marketing And Media - Apr 24 2013]

Entities: Cymbalta, Solanezumab, Eli Lilly & Company, DPP-4, Jan Lundberg

First reported Apr 20 2013 - Updated Apr 20 2013 - 1 reports

SITAGLIPTIN

More » Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type 2 Diabetes

According to the Institute for Safe Medication Practices? most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to pancreatic cancer. This class of medications is currently ... [Published Yahoo! News - Apr 20 2013]

Entities: Byetta, SITAGLIPTIN, Victoza, Pancreatic Cancer, pancreatitis

First reported Mar 15 2013 - Updated Mar 16 2013 - 1 reports

Can Diabetes Drugs Critics Say ‘I Told You So?’

Two weeks ago, a newly study indicated that a pair of widely used diabetes drugs – Merck’s Januvia and Bristol-Myers Squibb’s Byetta can double the risk of developing pancreatitis, which is an inflammation of the pancreas that is linked to cancer ... [Published Pharmalot - Mar 15 2013]

Entities: pancreatitis, Drugs, Diabetes

First reported Feb 28 2013 - Updated Mar 01 2013 - 1 reports

Cymbalta still tops in U.S. drug promotion list

The 10 most promoted drugs in the United States in 2012 were Cymbalta, Celebrex, Advair, Crestor, Pradaxa, Cialis, Bystolic, Symbicort, Viibryd, and Spiriva, according to Cegedim Strategic Data’s “2012 U.S . Pharmaceutical Spending Report.” Companies ... [Published Medad Blog - Feb 28 2013]

Entities: Cymbalta, Bystolic, Viibryd

First reported Jan 09 2013 - Updated Jan 10 2013 - 1 reports

Eli Lilly & Company

Eli Lilly: Buy, Sell Or Hold

ByPharma Reports: Eli Lilly ( LLY ) has just released 2013 revenue guidance of $23 billion (mid-range). According to Lilly's statement, that is single digit growth over 2012 final figures, which the company has not announced yet. Gross margin guidance ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 09 2013]

Entities: Eli Lilly & Company, Cymbalta, Patent, Humulin, Effient

First reported Jan 09 2013 - Updated Jan 09 2013 - 1 reports

Eli Lilly reassumes sole worldwide rights for basal insulin analog

Eli Lilly and Company and Boehringer Ingelheim International GmbH announced that they will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analogue, with Lilly reassuming sole worldwide ... [Published PharmaBiz - Jan 09 2013]

Entities: Eli Lilly & Company, Diabetes, Boehringer Ingelheim GmbH, Tradjenta

First reported Dec 15 2012 - Updated Dec 15 2012 - 1 reports

Germany's Price Reform Revolution

The Introduction in January 2011 of the Act on Reform of the Market for Pharmaceutical Products (AMNOG) has transformed the German pharmaceutical business like no law before, with significant long-term implications for the way companies develop and commercialize ... [Published Pharmaceutical Executive - Dec 15 2012]

Entities: IQWiG, AMNOG, Drugs, Germany, Rasilamlo

Quotes

...healthcare leaders and outstanding additions to our Board of Directors," said Mark B Logan, chairman of the BoardBoard of Directors of VIVUS. "Together Marty and Jorge bring, among other talents, extensive and valuable experience in commercialization, marketing and clinical studies, and we believe they will make immediate and significant contributions to the Board. We welcome Marty and Jorge and look forward to working closely with them to achieve our strategic objectives."

VIVUS Appoints J. Martin Carroll and Jorge Plutzky, M.D. to Board of Directors [Published Stockwatch - May 13 2013]

...The analysis showed reductions in HbA 1c from baseline with linagliptin versus placebo. "Response to treatment can vary between sub-populations of adults with type 2 diabetes" said Christophe Arbet-Engels

Retrospective Analysis Of Linagliptin Data In Sub-populations With Type 2 Diabetes Presented At A ... [Published TheStreet.com - May 06 2013]

...Physician at the Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland and Principal Investigator of the MARLINA trial. "What is of particular interest is that this study will evaluate the glycaemic efficacy and safety of linagliptin therapy in patients with type 2 diabetes whose kidneys are excreting significant amounts of albumin, a marker of both, kidney damage as well as an overall increased cardiovascular risk."

Boehringer Ingelheim, Lilly begin trial to evaluate use of linagliptin in patients with type 2 di ... [Published PharmaBiz - Mar 21 2013]

And our last report about Victoza was in November 2012: "The Drug-Induced Pancreatitis Safety Problem That Hangs Around Victoza Gets Another Look"

Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, An ... [Published Drug Injury Watch - Mar 18 2013]

More Content

sort by: Date \| Relevance
Potential Lawsuit: Diabetes Medication Lawsuits [Published Lawyers & Settlements - May 21 2013]
Tradjenta Coupon - The Things You Nee... [Published Al Bawaba - May 18 2013]
Vivus - Mild Drama Continues [Published Seeking Alpha - May 15 2013]
VIVUS Mails Letter to Stockholders Providing -2- [Published Scottrade - May 13 2013]
VIVUS CEO Issues Letter to Holders, Says In Dis... [Published Benzinga.com - May 13 2013]
VIVUS Mails Letter to Stockholders Providing Bu... [Published Morningstar.com - May 13 2013]
VIVUS Appoints J. Martin Carroll and Jorge Plut... [Published Stockwatch - May 13 2013]
The First Step in Treating Type 2 Diabetes [Published Motley Fool Discussion Boards - May 10 2013]
Alleged Januvia Pancreatic Cancer Lawsuits Offe... [Published PRWeb - May 10 2013]
Retrospective Analysis Of Linagliptin Data In S... [Published TheStreet.com - May 06 2013]
Higher prices keep Lilly's quarter flat; Cymbal... [Published Medical Marketing And Media - Apr 24 2013]
More » Report Shows Byetta, Januvia and Other I... [Published Yahoo! News - Apr 20 2013]
Watchdog Wants FDA To Ban Some Diabetes Drugs [Published Pharmalot - Mar 26 2013]
Boehringer Ingelheim, Lilly begin trial to eval... [Published PharmaBiz - Mar 21 2013]
Boehringer Ingelheim and Lilly initiate MARLINA... [Published PR Newswire: Health - Mar 19 2013]
Emerging Drug Safety Issue: Possible Increased ... [Published Drug Injury Watch - Mar 18 2013]
Can Diabetes Drugs Critics Say ‘I Told You So?’ [Published Pharmalot - Mar 15 2013]
FDA Investigating Januvia, Byetta and Other Dia... [Published PRWeb - Mar 15 2013]
Cymbalta still tops in U.S. drug promotion list [Published Medad Blog - Feb 28 2013]
Eli Lilly: Buy, Sell Or Hold [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 09 2013]
Eli Lilly reassumes sole worldwide rights for b... [Published PharmaBiz - Jan 09 2013]
Germany's Price Reform Revolution [Published Pharmaceutical Executive - Dec 15 2012]
Enrollment in CV outcome study of linagliptin v... [Published PharmaBiz - Nov 10 2012]
Diabetes Drug Launch 2012: Tip-tops and Promo-f... [Published Pharmaceutical Executive - Oct 12 2012]
Boehringer Ingelheim, Eli Lilly present data fr... [Published PharmaBiz - Oct 04 2012]
My Well Planner lifestyle improvement programme... [Published PharmaBiz - Sep 15 2012]
US FDA approves Tradjenta tabs for add-on thera... [Published PharmaBiz - Aug 20 2012]

Blogs

sort by: Date \| Relevance
Watchdog Wants FDA To Ban Some Diabetes Drugs [Published Pharmalot - Mar 26 2013] For the past month, a group of diabetes drugs have been under a microscope over concerns they cause not only pancreatitis, but also pre-cancerous cellular changes. Pancreatitis is actually not a new concern; the FDA issued alerts twice in recent years ...
Emerging Drug Safety Issue: Possible Increased ... [Published Drug Injury Watch - Mar 18 2013] As "Pancreatitis Is On The Pathway Toward Pancreatic Cancer", Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com ) We last wrote about ...
Can Diabetes Drugs Critics Say ‘I Told You So?’ [Published Pharmalot - Mar 15 2013] Two weeks ago, a newly study indicated that a pair of widely used diabetes drugs – Merck’s Januvia and Bristol-Myers Squibb’s Byetta can double the risk of developing pancreatitis, which is an inflammation of the pancreas that is linked to cancer ...
Cymbalta still tops in U.S. drug promotion list [Published Medad Blog - Feb 28 2013] The 10 most promoted drugs in the United States in 2012 were Cymbalta, Celebrex, Advair, Crestor, Pradaxa, Cialis, Bystolic, Symbicort, Viibryd, and Spiriva, according to Cegedim Strategic Data’s “2012 U.S . Pharmaceutical Spending Report.” Companies ...

Press Releases

sort by: Date \| Relevance
Boehringer Ingelheim and Lilly initiate MARLINA... [Published PR Newswire: Health - Mar 19 2013]